S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

$5.28
+0.14 (+2.72%)
(As of 03/1/2024 ET)
Today's Range
$5.13
$5.42
50-Day Range
$4.92
$9.91
52-Week Range
$4.80
$10.45
Volume
990,157 shs
Average Volume
1.20 million shs
Market Capitalization
$433.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Anavex Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
657.6% Upside
$40.00 Price Target
Short Interest
Bearish
24.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.58mentions of Anavex Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

Medical Sector

308th out of 950 stocks

Biological Products, Except Diagnostic Industry

49th out of 159 stocks


AVXL stock logo

About Anavex Life Sciences Stock (NASDAQ:AVXL)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

AVXL Stock Price History

AVXL Stock News Headlines

AVXL Mar 2024 6.000 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
AVXL Mar 2024 4.000 call
AVXL Feb 2024 7.000 call
AVXL Feb 2024 4.500 call
Anavex Life Sciences Corporation
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Anavex Life Sciences Earnings Preview
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
Anavex Life Sciences Corp (AVXL)
Anavex: The Pediatric Rett Trial Failure Is Disastrous
Anavex: The Pediatric Rett Trial Failure Is Disastrous
See More Headlines
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/03/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+657.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-47,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.65 per share

Miscellaneous

Free Float
72,588,000
Market Cap
$433.54 million
Optionable
Optionable
Beta
0.58
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Christopher U. Missling M.B.A. (Age 58)
    M.S., Ph.D., President, CEO, Secretary & Director
    Comp: $828.25k
  • Ms. Sandra Boenisch CPA (Age 43)
    CGA, Principal Financial Officer & Treasurer
    Comp: $194.36k
  • Mr. Stephan Toutain M.B.A. (Age 58)
    M.S., Senior VP of Operations & COO
  • Dr. Walter E. Kaufmann M.D.
    Chief Scientific Officer
  • Clint Tomlinson
    VP of Corporate
  • Dr. Adebayo Laniyonu Ph.D.
    Senior Vice President of Nonclinical Development
  • Dr. Edward R Hammond M.D.
    M.P.H., Ph.D., Chief Medical Officer
  • Dr. Kun Jin Ph.D.
    Head of Biostatistics
  • Mr. David Goldberger R.Ph.
    Senior Vice President of Regulatory Affairs














AVXL Stock Analysis - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for Anavex Life Sciences' stock. Their AVXL share price targets range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 657.6% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2024?

Anavex Life Sciences' stock was trading at $9.31 at the beginning of 2024. Since then, AVXL stock has decreased by 43.3% and is now trading at $5.28.
View the best growth stocks for 2024 here
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) released its quarterly earnings data on Wednesday, February, 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04.

What ETF holds Anavex Life Sciences' stock ?

iShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.31%), DLD Asset Management LP (0.00%), Nwam LLC (0.97%), Northern Trust Corp (0.90%), Charles Schwab Investment Management Inc. (0.76%) and SG Americas Securities LLC (0.37%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends
.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVXL) was last updated on 3/3/2024 by MarketBeat.com Staff